Core One Labs has announced that its wholly-owned subsidiary Akome Biotech, has entered into an agreement with the Universidad Complutense de Madrid to carryout neurogenesis stimulation and modelling studies research, to advance the development of the company’s patent-pending psychedelic bioactive compounds that target Alzheimer’s Disease, Parkinson’s Disease, Major Depressive Disorder and Ischemic Stroke.
Category Press Release
Published in Core One Lbas